JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

Recruiting now · Not applicable

Conditions studied: Androgenetic Alopecia, Androgenic Alopecia

In brief

Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.

Key facts

Study ID

NCT07563036

Run by

Kasr El Aini Hospital

People needed

25

Starts

2026-02-01

Expected to finish

2027-01-01

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Male adults aged 18 to 50 years with androgenetic alopecia.
• Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
• Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
• Willing and able to provide written informed consent.

You may not qualify if…

• Other types of hair loss, including inflammatory or scarring alopecia.
• Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
• Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
• History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
• Chemotherapy during the last 5 years.
• Bleeding disorders.

Where it is running

• Kasr El Aini Hospital — Cairo, Cairo Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.